Prattipati Laxminarain serves as Independent Director of the Company. From April 2006 through October 2017, Mr. Laxminarain served as Worldwide President at Codman Neuro, a global neurosurgery and neurovascular company that offers a portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery and other technologies, and which was part of DePuy Synthes Companies of Johnson & Johnson. Mr. Laxminarain is currently the CEO of Deinde Medical Corporation, and is a Board Member of Oculogica Inc., Millar Inc., and GT Medical Inc. He has a degree in Mechanical Engineering from Osmania University, Hyderabad, India and an MBA from Indian Institute of Management. The Company believes that Mr. Laxminarain is qualified as a Board member of the Company because of his extensive experience working with medical device companies and knowledge of the industries in which the Company intends to compete.
Prattipati Laxminarain is 62, he's been the Independent Director of Microbot Medical Inc since 2017. There are 1 older and 11 younger executives at Microbot Medical Inc. The oldest executive at Microbot Medical Inc is Prof. Moshe Shoham, 69, who is the Co-Founder, Scientific Director & Member of Scientific Advisory Board.
Prattipati's mailing address filed with the SEC is C/O MICROBOT MEDICAL INC., 288 GROVE STREET, SUITE 388, BRAINTREE, MA, 02184.
Over the last 8 years, insiders at Microbot Medical Inc have traded over $5,894,432 worth of Microbot Medical Inc stock and bought 10,000 units worth $11,000 . The most active insiders traders include Yoseph Bornstein, Investment Management Ltd A..., and Moshe Shoham. On average, Microbot Medical Inc executives and independent directors trade stock every 37 days with the average trade being worth of $46,188. The most recent stock trade was executed by Yoseph Bornstein on 19 October 2020, trading 4,881 units of MBOT stock currently worth $38,755.
microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac
Microbot Medical Inc executives and other stock owners filed with the SEC include: